Search

OBJECTIVE: To observe the clinical efficacy of Siwu Wuzi decoction on macular edema secondary to central retinal vein occlusion. METHODS: A total of 100 patients with macular edema secondary to central retinal vein occlusion admitted into the Qingdao Traditional Chinese Medicine Hospital from Jan. 2020 to Jan. 2022 were extracted to be divided into the control group and the treatment group via the random number table. Fifty patients in the control group were treated with conventional western medicine, while 50 patients in the treatment group received Siwu Wuzi decoction on the basis of the control group. Levels of monocyte chemoattractant protein-1 (MCP-1), endothelin-1 (ET-1), soluble intercellular adhesion molecule-1 ( sICAM-1), matrix metalloproteinase 2 ( MMP-2), vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNF-α), and tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), interleukin-8 (IL-8), fibrinogen, erythrocyte sedimentation rate, and plasma viscosity before and after treatment were detected in two groups. The flow density of choroidal capillary layer (CFD), the blood flow density (FD300 ) of the 300 μm wide area next to the foveal avascular area, and the macula central retinal thickness (CMT) and best-corrected visual acuity (BCVA) were observed. And the macular edema regressed in the patients were recorded, the clinical efficacy were compared. RESULTS: After treatment, the contents of MCP-1, ET-1, sICAM-1 and VEGF in the treatment group group were significantly lower than those in the control group, the contents of MMP-2, TNF-α and IL-8 were lower than those in the control group, the TIMP-2 in was higher than that in the control group, the erythrocyte sedimentation rate, fibrinogen and plasma viscosity were significantly lower than those in the control group, with statistically significant differences (P<0. 05). After treatment, CFD and CMT in the treatment group were significantly lower than those in the control group, FD300 and BCVA were significantly higher than those in the control group, and the macular edema regression was significantly better than that in the control group, with statistically significant differences (P<0. 05). The total effective rate of the treatment group was 98. 00% (49/50), significantly higher than 88. 00% (44/50) of the control group, the difference was statistically significant (P<0. 05). CONCLUSIONS: Siwu Wuzi decoction in the treatment of macular edema secondary to central retinal vein occlusion can reduce vascular endothelial damage, decrease the levels of MMP-2, TNF-α and IL-8, inhibit inflammation, improve hemorheology and choroidal microcirculation and patients’ vision, promote the regression of macular edema with significant clinical efficacy. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Angle Health Law Review is the property of Angle Publishing Co., Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)